, related to Experimental Procedures. Cartoon diagram of the extracorporeal circuit setup. Sample whole blood is collected into a syringe attached to tubing that feeds into a reservoir. Blood is pumped from the reservoir via a mechanical roller pump to the oxygenator membrane, where the blood is heated to approximately 30°C and supplied with 95% O 2 and 5% CO 2 . Blood exits the membrane flows through a flow probe that monitors the flow rate, and is returned to the reservoir. Samples can be removed at any time through a small opening in the top of the reservoir. The circuit is run in a continual loop for 2 hours, or until clot formation is observed. 
SUPPLEMENTAL TABLES

SUPPLEMENTAL EXPERIMENTAL PROCEDURES
Modified RNA aptamers and DNA antidotes: The FIXa aptamer (Rusconi, et al., 2002 ) (9.3T; 5'-AUGGGGACUAUACCGCGUAAUGCUGCCUCCCCAU-3'), FXa aptamer (Buddai, et al., 2010) (11F7T; 5'-GAGAGCCCCAGCGAGAUAAUACUUGGCCCCGCUCUU-3'), prothrombin aptamer (Bompiani, et al., 2012 ) (R9D-14T7; 5'-GGCGGTCGATCACACAGTTCAAACGTAATAAGCCAATGTACGAGGCAGACGACTCGCC -3'),
and FIXa mutant control aptamer (Rusconi, et al., 2002 ) (9.3Tmut; 5'-AUGGGGACUGUGCCGCGUAAUGCUGCCUCCCCAU-3') were purchased from ST Pharm Co., Ltd.
The FVIIa aptamer (Layzer and Sullenger, 2007 ) (7S-1; 5'-GGGAGGACGAUGCGGACUCCUCCAAGCGACCAACAUCGGUCCCGUUUCAGAUCAACAGAC GACUCGCUGAGGAUCCGAGA-3'), FXa mutant control aptamer (Buddai, et al., 2010 ) (11F7Tmut;
5'-GAGAGCCCCAGCGAGAUAAUACUUGUACCCGCUCUU -3'), prothrombin mutant control aptamer (Bompiani, et al., 2012 ) (R9D-14Tmut 5'-
and FVIIa mutant control aptamer (7S-1mut; 5'-GGGAGGACGAUGCGGACUCCUCCAAGCGACCAACAUCGGUCUUAUUUCAGAUCAA CAGACGACUCGCUGAGGAUCCGAGA-3') (unpublished) were transcribed and purified using in vitro methods previously described (Layzer and Sullenger, 2007) . For all of the RNA aptamers the pyrimidines are modified ribonucleotides, where "C" denotes a 2'Fluorocytosine and "U" denotes a 2'Fluorouracil. Prior to all functional assays, the aptamers were diluted in Hepes/saline buffer (20 mM Hepes, pH 7.4, 150 mM NaCl, and 2 mM CaCl 2 ), heated to 65°C for 5 min, and cooled to ambient temperature for 3 min to re-nature the RNA. For combinations of two aptamers, the aptamers were diluted and heated/cooled separately and then combined on ice to prevent potential inter-molecular interactions.
The FXa aptamer complementary DNA antidote (5'-TATTATCTCGCTGGG -3') and the prothrombin aptamer complementary DNA antidote (5'-GTCTGCCTCGTACATTGGCT-3') were designed via Watson-Crick base pairing as previously described (Bompiani, et al., 2012) Aptamer synergy calculations: Drug synergy for aptamer combinations in the aPTT and PT was assessed with the algebraic method described by Berenbaum (Berenbaum, 1977) . Drug synergy was calculated according to the following equation:
where A e and B e are concentrations of the individual aptamers that produce equivalent clotting times, and "dose of A" and "dose of B" are the respective concentrations of aptamers when tested in combination that produce the same clotting time as A e and B e . Additive aptamer combinations were defined as combinations that have a sum of fractions equal to one, while synergistic aptamer combinations were defined as combinations that have a sum less than one.
